Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
about
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesPotent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 ProteinCombination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.Tsetse salivary gland hypertrophy virus: hope or hindrance for tsetse control?A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Smallpox vaccines: targets of protective immunity.An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodiesHumoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.Vaccinia virus A26 and A27 proteins form a stable complex tethered to mature virions by association with the A17 transmembrane protein.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complementHeavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses.The smallpox vaccine induces an early neutralizing IgM response.Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.Recombinant Sheep Pox Virus Proteins Elicit Neutralizing Antibodies
P2860
Q27325586-DD228FA2-70A2-4E73-9FF7-18019BA0E5E7Q27684713-3C64C4C7-0EF7-40B2-B368-DFBC0D570DCCQ33967713-40FF670D-C2B4-44D5-B733-7AD9955F6D58Q34017981-B87016A4-5609-47D4-912E-7B3A0574ED20Q34126697-B399D0DE-D065-4034-AAE5-9A354B8278A7Q34780607-C13C13ED-0F24-43D1-AEAF-09C9A60D3590Q35186318-57C26843-F7E3-4037-B200-713B9B280157Q36559636-B4F2FA20-47BA-4E6C-95DC-83798E6558F4Q36811880-66F382B0-0D6F-4099-8EC3-8C85912F46A8Q36994647-0183FBF7-49C3-41FD-A3DB-F34FDFD1AC35Q37051617-5068F7A4-598B-4D16-A444-911B0A04DBAFQ37452067-E1A9D514-D8AF-4713-BF75-F74E1DB077A6Q37452527-F442823A-4716-4AF7-A53A-9DE6496123FFQ37456873-6A54B1BA-8C4C-4E6F-98A3-E840DB633038Q37791160-F9CBCD7D-98BD-4C9E-8B9B-7891625BA996Q40684847-B0FA1FE1-A78C-46A9-B687-56214751F129
P2860
Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Disparity between levels of in ...... against intranasal challenge.
@en
type
label
Disparity between levels of in ...... against intranasal challenge.
@en
prefLabel
Disparity between levels of in ...... against intranasal challenge.
@en
P2093
P2860
P356
P1433
P1476
Disparity between levels of in ...... against intranasal challenge.
@en
P2093
Christiana N Fogg
Gary H Cohen
Jeffrey L Americo
Lydia Aldaz-Carroll
Patricia L Earl
Wolfgang Resch
P2860
P304
P356
10.1128/JVI.00568-08
P407
P577
2008-06-04T00:00:00Z